PTPN11 and cancer: RMC-4550-treated tumours were characterised by a further elevated presence of T cells compared to tumours treated with RMC-4998, which was also reflected in tumours treated with combined targeted therapy, again pointing towards additional effects of SHP2 inhibition on the TME independent of any effect on cancer-cell signalling (Fig. 6a, b).